Skip to Content

NTRK2 (SDL12058)

https://www.scanlabglobal.com/web/image/product.template/6743/image_1920?unique=18393fc
Tests NTRK2 fusions in tumors for targeted therapy eligibility. Positive results guide larotrectinib for NTRK-driven malignancies.

1,480.00 AED 1480.0 AED 1,480.00 AED

1,480.00 AED

Not Available For Sale

This combination does not exist.